Aneurysm Occlusion Member With Rupturable Coupler Neck Sealing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for intracranial aneurysms, such as platinum coil and flow diverter methods, face challenges with long-term recanalization and the need for antiplatelet therapy, which can be risky, especially in cases with wide necks or large interior volumes, necessitating a more effective and immediate solution for aneurysm closure.

Innovation Solution

A treatment system comprising an occlusive member with a coupler that can deform or rupture to decouple from a delivery conduit, allowing for the deployment of an embolic element to transform the occlusive member into a second expanded state, providing a stable seal at the aneurysm neck and reducing recanalization risk.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If platinum coil is disposed within the aneurysm to induce thrombus formation, then the aneurysm closure is achieved over time, but long-term recanalization occurs especially for aneurysms with wide necks and large interior volumes

Engineering Contradiction:
Improveaneurysm closure stabilityVSAvoidtime for recanalization
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The device segments the aneurysm treatment into two functional components: an occlusive member that provides immediate mechanical blockage and an embolic element that delivers therapeutic agents. This segmentation allows the occlusive member to prevent recanalization while the embolic element promotes stable thrombus formation, addressing both the reliability and time-loss issues.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The device combines an occlusive member (such as a mesh or braid structure) with an embolic element containing therapeutic agents. This composite structure provides both immediate mechanical occlusion to prevent recanalization and pharmacological promotion of stable thrombus formation, thereby improving closure stability and reducing recanalization risk.

Inventive Principle:
Principle #40Composite materials

2Reliability

If flow diverter is deployed to cause blood stagnation and thrombus formation, then aneurysm closure is achieved, but it takes weeks or months for full effect and antiplatelet therapy is required

Engineering Contradiction:
Improveaneurysm closure effectivenessVSAvoidtime to achieve closure
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The occlusive member is designed to provide immediate preliminary occlusion upon deployment, blocking blood flow into the aneurysm sac right away. This preliminary mechanical blockage eliminates the weeks or months delay associated with flow diverters, as the aneurysm is occluded immediately rather than waiting for thrombus formation.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The embolic element acts as an intermediary that delivers therapeutic agents (such as growth factors or anticoagulants) directly to the aneurysm site. This intermediary function promotes rapid and stable thrombus formation without requiring systemic antiplatelet therapy, thereby achieving reliable closure faster while avoiding the bleeding risks associated with antiplatelet medications.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If antiplatelet therapy is used to prevent thrombus in the main channel, then thrombus formation in the aneurysm is prevented, but risk of re-rupture increases especially after initial rupture

Engineering Contradiction:
Improvethrombus prevention in main channelVSAvoidrisk of re-rupture
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The device applies different functional qualities to different locations: the occlusive member provides local mechanical occlusion at the aneurysm neck to promote thrombus formation within the aneurysm sac, while the embolic element delivers localized therapeutic agents. This local action eliminates the need for systemic antiplatelet therapy, thereby preventing thrombus in the main channel without increasing re-rupture risk.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The embolic element serves as a localized intermediary that delivers therapeutic agents directly to the aneurysm site, replacing the need for systemic antiplatelet therapy. This localized intervention promotes thrombus formation only where needed (in the aneurysm) without affecting the main channel, thereby preventing re-rupture while still achieving aneurysm occlusion.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS11305387B2Systems and methods for treating aneurysms
Publication Date: 2022.04.19 COVIDIEN LP
  • US11305387B2 patent drawing
  • US11305387B2 patent drawing
  • US11305387B2 patent drawing

AI summary

An aneurysm treatment system can include an occlusive member configured to be positioned within an aneurysm sac, and a distal conduit coupled to the occlusive member and having a first lumen extending therethrough. A proximal conduit has a second lumen extending therethrough and is positioned adjacent the distal conduit so that the first lumen is in fluid communication with the second lumen. A coupler extends between the distal conduit and the proximal conduit. The coupler may be ruptured to permit the proximal conduit and the distal conduit to be separated from one another.